Results 131 to 140 of about 8,771 (219)

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra, B. Botella, M. D. Martín‐Arranz, D. Ceballos, C. Martínez‐Pascual, A. Garrido, P. Varela, M. Moreta, E. Brunet‐Mas, Y. González‐Lama, E. Rodríguez‐González, M. Vicuña, J. P. Gisbert, I. Ordás, F. Argüelles‐Arias, J. Tosca‐Cuquerella, R. Vicente‐Lidón, M. Sierra‐Ausín, I. Rodríguez‐Lago, D. Martín‐Rodríguez, J. M. Paredes, B. Sicilia, I. García de la Filia, N. Jiménez, M. Barreiro‐de Acosta, E. Betoré, I. Ferrer‐Bradley, L. García‐Alles, J. M. Huguet, S. Castellet‐Farrús, M. J. García, A. Gutiérrez‐Casbas, Á. Ponferrada‐Díaz, L. Ramos, M. Calafat, I. Vera, C. Suárez‐Ferrer, E. Fernández‐Velado, S. Rodríguez‐Sánchez, A. Mínguez, A. Mancebo, J. Barrio, S. Lario, D. R. de La Cruz, Alejandro Hernández‐Camba, C. Rodríguez‐Gutiérrez, M. Chaparro, E. Ricart, L. Almenara‐Michelena, A. Balaguer, E. Domènech, P. Nos   +51 more
wiley   +1 more source

Infections in Patients with Atopic Dermatitis and the Infuence of Treatment [PDF]

Atopic dermatitis (AD) is a T helper 2-mediated chronic infammatory skin disease that afects children and adults. Patients with AD are prone to recurrent infections of the skin and other organs, which can severely worsen the disease course. This review
Maddalena Napolitano, · Caterina Foti, · Elena Nicoli, · Giampiero Girolomoni, · Maria Concetta Fargnoli, · Maria Esposito, · Paolo Matruglio, · Paolo Romita   +7 more
core   +1 more source

Oral lichenoid lesions in CTLA‐4 haploinsufficiency: Targeting IFN‐γ‐driven mucosal immunopathology

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chen Wang, Laurie Brenchley, Teresa Greenwell‐Wild, Vasileios Ionas Theofilou, Timothy G. Myers, Chi A. Ma, Katherine Howe, Stefania Pittaluga, Steven M. Holland, Niki M. Moutsopoulos, David Fraser, Gulbu Uzel   +11 more
wiley   +1 more source

Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US

The Journal of Dermatology, Volume 53, Issue 5, Page 758-773, May 2026.
ABSTRACT Vitiligo is a chronic autoimmune depigmenting disease characterized by loss of pigment in the skin, hair, or both. As treatment options evolve, particularly with the emergence of oral Janus kinase inhibitors and dual Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor, it is essential to assess ...
Kennedy Cook, Nada M. Elbuluk, Roni Adiri, Alexandre Lejeune, Thomas Edwards, Milena A. Gianfrancesco, Scott P. Kelly, Tatjana Lukic, Edward Nagy, Samantha K. Kurosky, Lynne Napatalung, Iltefat Hamzavi   +11 more
wiley   +1 more source

Off-label use of upadacitinib in dermatology: a review

Journal of Dermatological Treatment
Objectives Upadacitinib, a selective JAK1 inhibitor, is approved for the treatment of atopic dermatitis but is increasingly used off-label in dermatology.
Hongtao Yu, Junkai Zhu, Xiaoli Ni, Kaiyu Yu, Zhen Mu   +4 more
doaj   +1 more source

T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets

Aging Cell, Volume 25, Issue 5, May 2026.
Immunosenescent T cells promote inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, and seborrheic dermatitis via hyperactive signaling networks and SASP secretion. Consequently, intercepting downstream SASP, inhibiting internal pathways, or utilizing senolytics represents promising therapeutic interventions.
Conghui Liu, Ming Yang, Fugang Xiao, Jinrong Zeng   +3 more
wiley   +1 more source

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Arthritis Research & Therapy
Background The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS 2 study ...
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert Davies Inman, Hideto Kameda, Walter Peter Maksymowych, Ivan Lagunes-Galindo, Xianwei Bu, Peter Wung, Koji Kato, Anna Shmagel, Atul Deodhar   +11 more
doaj   +1 more source

Against Moral Panic and Citation Fiction: A Critique of “Panem, Corticoids and Circenses” and a Proposal for Editorial Gatekeeping on Reference Integrity

Bioethics, Volume 40, Issue 4, Page 365-372, May 2026.
ABSTRACT The proposed Enhanced Games have become a convenient stage for bioethical sermonising about risk, authenticity, and the “spirit of sport”. This is epitomized by a recent article arguing that institutionalizing pharmacological enhancement under the “pretence of medical supervision and personal autonomy” would redefine human excellence in ...
Ognjen Arandjelović
wiley   +1 more source

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 856-866, May 2026.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source